Chemotherapeutic resistance: Surviving stressful situations

Cancer Research

Volumn 71, Issue 15, 2011, Pages 5062-5066

  Gilbert, Luke A ^a   Hemann, Michael T ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; IMATINIB; INTERLEUKIN 6; JANUS KINASE INHIBITOR; NOTCH RECEPTOR; SONIC HEDGEHOG PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; WNT PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; B CELL LEUKEMIA; BLOOD BRAIN BARRIER; BURKITT LYMPHOMA; CANCER CELL; CANCER MORTALITY; CANCER RESISTANCE; CANCER SURVIVAL; CELL PROTECTION; CELL STRESS; COMBINATION CHEMOTHERAPY; DNA DAMAGE; DRUG EFFICACY; DRUG POTENCY; EMBRYO DEVELOPMENT; GENOTOXICITY; HOMEOSTASIS; HUMAN; LARGE CELL LYMPHOMA; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LUNG CANCER; LYMPHOMA CELL; MONOTHERAPY; NONHUMAN; OVERALL SURVIVAL; PARACRINE SIGNALING; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SERODIAGNOSIS; STEM CELL; TISSUE REGENERATION; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL SURVIVAL; DNA DAMAGE; DNA, NEOPLASM; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ENDOTHELIAL CELLS; HUMANS; INTERLEUKIN-6; LYMPHOMA, B-CELL; MICE; NEOPLASM TRANSPLANTATION; NEOPLASM, RESIDUAL; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PARACRINE COMMUNICATION; STROMAL CELLS; THYMECTOMY; THYMUS GLAND; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TUMOR MICROENVIRONMENT;

EID: 79960958310     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-0277     Document Type: Review

References (36)

1. Egeblad M, Nakasone ES, Werb Z. Tumors as organs: complex tissues that interface with the entire organism. Dev Cell 2010;18:884-901.
2. Goss PE, Chambers AF. Does tumour dormancy offer a therapeutic target? Nat Rev Cancer 2010;10:871-7.
3. Cavé H, van der Werff ten Bosch J, Suciu S, Guidal C, Waterkeyn C, Otten J, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer-Childhood Leukemia Cooperative Group. N Engl J Med 1998;339:591-8.
4. Brisco MJ, Condon J, Hughes E, Neoh SH, Sykes PJ, Seshadri R, et al. Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction. Lancet 1994;343:196-200.
5. Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 2007;7:834-46. (Pubitemid 350006258)
6. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med 2002;53:615-27. (Pubitemid 34177898)
7. Jiang H, Reinhardt HC, Bartkova J, Tommiska J, Blomqvist C, Nevanlinna H, et al. The combined status of ATM and p53 link tumor development with therapeutic response. Genes Dev 2009;23:1895-909.
8. Gupta PB, Chaffer CL, Weinberg RA. Cancer stem cells: mirage or reality? Nat Med 2009;15:1010-2.
9. Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, Cory S, et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 1985;318:533-8. (Pubitemid 16173038)
10. Gilbert LA, Hemann MT. DNA damage-mediated induction of a chemoresistant niche. Cell 2010;143:355-66.
11. Lee S, Choi I, Hong YK. Heterogeneity and plasticity of lymphatic endothelial cells. Semin Thromb Hemost 2010;36:352-61.
12. Coppé JP, Patil CK, Rodier F, Sun Y, Muñoz DP, Goldstein J, et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol 2008;6:2853-68.
13. Pasquier E, Kavallaris M, André N. Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol 2010;7:455-65.
14. Shaked Y, Henke E, Roodhart JM, Mancuso P, Langenberg MH, Colleoni M, et al. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 2008;14:263-73.
15. Shaked Y, Ciarrocchi A, Franco M, Lee CR, Man S, Cheung AM, et al. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 2006;313:1785-7. (Pubitemid 44454154)
16. Abeloff MD. Abeloff's clinical oncology. 4th ed. Philadelphia: Churchill Livingstone/Elsevier; 2008.
17. Barth TF, Leithäuser F, Joos S, Bentz M, Möller P. Mediastinal (thymic) large B-cell lymphoma: where do we stand? Lancet Oncol 2002;3:229-34. (Pubitemid 34436659)
18. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer 2006;6:583-92. (Pubitemid 44140857)
19. Meads MB, Hazlehurst LA, Dalton WS. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res 2008;14:2519-26.
20. Kikuchi K, Lai AY, Hsu CL, Kondo M. IL-7 receptor signaling is necessary for stage transition in adult B cell development through up-regulation of EBF. J Exp Med 2005;201:1197-203. (Pubitemid 40629064)
21. Beachy PA, Karhadkar SS, Berman DM. Tissue repair and stem cell renewal in carcinogenesis. Nature 2004;432:324-31. (Pubitemid 39551660)
22. McDonald B, Pittman K, Menezes GB, Hirota SA, Slaba I, Waterhouse CC, et al. Intravascular danger signals guide neutrophils to sites of sterile inflammation. Science 2010;330:362-6.
23. Butler JM, Nolan DJ, Vertes EL, Varnum-Finney B, Kobayashi H, Hooper AT, et al. Endothelial cells are essential for the self-renewal and repopulation of Notch-dependent hematopoietic stem cells. Cell Stem Cell 2010;6:251-64.
24. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;140:883-99.
25. Chatterjee M, Osborne J, Bestetti G, Chang Y, Moore PS. Viral IL-6-induced cell proliferation and immune evasion of interferon activity. Science 2002;298:1432-5. (Pubitemid 35346145)
26. Cressman DE, Greenbaum LE, DeAngelis RA, Ciliberto G, Furth EE, Poli V, et al. Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science 1996;274:1379-83. (Pubitemid 26391463)
27. Rebouissou S, Amessou M, Couchy G, Poussin K, Imbeaud S, Pilati C, et al. Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature 2009;457:200-4.
28. Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 2011;470:115-9.
29. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-61. (Pubitemid 40386783)
30. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 2007;7:585-98. (Pubitemid 47106630)
31. Trikha M, Corringham R, Klein B, Rossi JF. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res 2003;9:4653-65. (Pubitemid 37323267)
32. Yao Z, Fenoglio S, Gao DC, Camiolo M, Stiles B, Lindsted T, et al. TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proc Natl Acad Sci U S A 2010;107:15535-40.
33. Williams RT, den Besten W, Sherr CJ. Cytokine-dependent imatinib resistance in mouse BCR-ABL+, Arf-null lymphoblastic leukemia. Genes Dev 2007;21:2283-7. (Pubitemid 47443334)
34. Jones SA, Horiuchi S, Topley N, Yamamoto N, Fuller GM. The soluble interleukin 6 receptor: mechanisms of production and implications in disease. FASEB J 2001;15:43-58. (Pubitemid 32061655)
35. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007;317:121-4. (Pubitemid 47056470)
36. Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008;359:1995-2004.